Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rodney H Breau

Showing results (221-230 of 253) with videos related to

Pageof 26
Sort By:
Cancers|February 13, 2025
Real-World Efficacy and Toxicity of Ipilimumab and Nivolumab as First-Line Treatment of Metastatic Renal Cell Carcinoma (mRCC) in a Subpopulation of Elderly and Poor Performance Status PatientsNoa Shani Shrem, Ana-Alicia Beltran-Bless, Sunita Ghosh, et al.
International Journal of Radiation Oncology, Biology, Physics|August 26, 2024
Effect of Complete Transurethral Resection on Oncologic Outcomes After Radiation Therapy for Muscle-Invasive Bladder CancerPier Paolo Avolio, Ronald Kool, Bobby Shayegan, et al.
European Urology Focus|November 5, 2021
Outcomes of Cytoreductive Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Real World Data from Canadian CentersAlice Dragomir, Sara Nazha, Simon Tanguay, et al.
European Urology Oncology|December 14, 2023
Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic TherapiesGhady Bou-Nehme Sawaya, Alice Dragomir, Lori A Wood, et al.
The Journal of Urology|July 25, 2024
The Impact of Histologic Subtypes on Clinical Outcomes After Radiation-Based Therapy for Muscle-Invasive Bladder CancerDaniel Halstuch, Ronald Kool, Gautier Marcq, et al.
The Oncologist|August 4, 2025
Real-world assessment of clinical outcomes of first-line treatment in metastatic papillary Renal Cell CarcinomaManon De Vries-Brilland, Zineb Hamilou, Sunita Ghosh, et al.
Current Oncology (Toronto, Ont.)|May 26, 2026
Forecasting Trends in Androgen Deprivation Therapy Intensification for Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Population-Based Cohort and Time-Series AnalysisEalia Khosh Kish, Erind Dvorani, Refik Saskin, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|October 2, 2020
Prognostic impact of paraneoplastic syndromes on patients with non-metastatic renal cell carcinoma undergoing surgery: Results from Canadian Kidney Cancer information systemRyan Sun, Rodney H Breau, Ranjeeta Mallick, et al.
Clinical Genitourinary Cancer|March 6, 2026
Node Positive Resected Renal Cell Carcinoma Portends a Poor Prognosis: Results From the Canadian Kidney Cancer CollaborationJesse Tr Spooner, Christopher Bitcon, Wyatt MacNevin, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|December 17, 2025
Development of a reoperative risk prediction model of muscle-invasive upper tract urothelial carcinoma using clinical and radiomic computed tomography features: Initial results from a multi-institutional Canadian studyDavid-Dan Nguyen, Paola V Nasute Fauerbach, Jethro C C Kwong, et al.
Pageof 26

Showing results (221-230 of 253) with videos related to

Sort By:
Pageof 26
Cancers|February 13, 2025
Real-World Efficacy and Toxicity of Ipilimumab and Nivolumab as First-Line Treatment of Metastatic Renal Cell Carcinoma (mRCC) in a Subpopulation of Elderly and Poor Performance Status PatientsNoa Shani Shrem, Ana-Alicia Beltran-Bless, Sunita Ghosh, et al.
International Journal of Radiation Oncology, Biology, Physics|August 26, 2024
Effect of Complete Transurethral Resection on Oncologic Outcomes After Radiation Therapy for Muscle-Invasive Bladder CancerPier Paolo Avolio, Ronald Kool, Bobby Shayegan, et al.
European Urology Focus|November 5, 2021
Outcomes of Cytoreductive Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Real World Data from Canadian CentersAlice Dragomir, Sara Nazha, Simon Tanguay, et al.
European Urology Oncology|December 14, 2023
Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic TherapiesGhady Bou-Nehme Sawaya, Alice Dragomir, Lori A Wood, et al.
The Journal of Urology|July 25, 2024
The Impact of Histologic Subtypes on Clinical Outcomes After Radiation-Based Therapy for Muscle-Invasive Bladder CancerDaniel Halstuch, Ronald Kool, Gautier Marcq, et al.
The Oncologist|August 4, 2025
Real-world assessment of clinical outcomes of first-line treatment in metastatic papillary Renal Cell CarcinomaManon De Vries-Brilland, Zineb Hamilou, Sunita Ghosh, et al.
Current Oncology (Toronto, Ont.)|May 26, 2026
Forecasting Trends in Androgen Deprivation Therapy Intensification for Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Population-Based Cohort and Time-Series AnalysisEalia Khosh Kish, Erind Dvorani, Refik Saskin, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|October 2, 2020
Prognostic impact of paraneoplastic syndromes on patients with non-metastatic renal cell carcinoma undergoing surgery: Results from Canadian Kidney Cancer information systemRyan Sun, Rodney H Breau, Ranjeeta Mallick, et al.
Clinical Genitourinary Cancer|March 6, 2026
Node Positive Resected Renal Cell Carcinoma Portends a Poor Prognosis: Results From the Canadian Kidney Cancer CollaborationJesse Tr Spooner, Christopher Bitcon, Wyatt MacNevin, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|December 17, 2025
Development of a reoperative risk prediction model of muscle-invasive upper tract urothelial carcinoma using clinical and radiomic computed tomography features: Initial results from a multi-institutional Canadian studyDavid-Dan Nguyen, Paola V Nasute Fauerbach, Jethro C C Kwong, et al.
Pageof 26